Halozyme Could Get $83M in Licensing Deal

5/11/11Follow @bvbigelow

San Diego’s Halozyme Therapeutics (NASDAQ: HALO) says it will receive an upfront payment of $9 million and potential future milestone payments of $74 million under an exclusive worldwide licensing agreement with Exton, PA-based ViroPharma (NASDAQ: VPHM). Halozyme is licensing the use of its recombinant human hyaluronidase in the development of a subcutaneous formulation of human C1 esterase inhibitor. ViroPharma develops proprietary pharmaceuticals to treat influenza, viral Pneumonia, Hepatits C, and other viral diseases.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

By posting a comment, you agree to our terms and conditions.